Get the Stockscreener App
1.84
0.54%
-0.01
After Hours:
1.84
Omniab Inc stock is traded at $1.84, with a volume of 184.38K.
It is down -0.54% in the last 24 hours and down -5.64% over the past month.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
See More
Previous Close:
$1.85
Open:
$1.83
24h Volume:
184.38K
Relative Volume:
0.35
Market Cap:
$264.88M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-3.622
EPS:
-0.508
Net Cash Flow:
$703.00K
1W Performance:
-1.08%
1M Performance:
-5.64%
6M Performance:
-4.66%
1Y Performance:
-50.40%
1-Day Range:
$1.81
$1.87
1-Week Range:
$1.80
$1.94
52-Week Range:
$1.22
$4.02
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.84 | 266.32M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
OmniAb, Inc. (NASDAQ:OABI) has caught the attention of institutional investors who hold a sizeable 36% stake - Yahoo Finance
Is OmniAb Inc a good long term investmentEquity Performance Review & Free Proven Portfolio Growth Strategies - earlytimes.in
Aug Swings: What analyst consensus says on OmniAb Inc stockWeekly Market Outlook & High Win Rate Trade Alerts - moha.gov.vn
Why OmniAb Inc. stock is rated strong buyExit Point & Real-Time Stock Movement Alerts - Улправда
Can OmniAb Inc. stock resist market sell offsChart Signals & Community Consensus Trade Alerts - ulpravda.ru
Why retail investors pile into OmniAb Inc. Equity Warrant stockRisk Management & Community Trade Idea Sharing Platform - Улправда
Will OmniAb Inc. Equity Warrant stock return to pre crisis levelsJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - DonanımHaber
Market Rankings: Is OmniAb Inc. Equity Warrant stock a smart buy before Fed meeting2025 Pullback Review & Weekly Sector Rotation Insights - DonanımHaber
How OmniAb Inc. stock reacts to job market dataOil Prices & Weekly Setup with High ROI Potential - DonanımHaber
What analyst consensus says on OmniAb Inc. stock2025 Analyst Calls & Verified Momentum Watchlists - DonanımHaber
Will OmniAb Inc. Equity Warrant stock sustain high P E ratiosJuly 2025 Outlook & Expert Verified Stock Movement Alerts - DonanımHaber
Is OmniAb Inc. Equity Warrant stock supported by strong cash flowsMarket Sentiment Report & Comprehensive Market Scan Reports - Улправда
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail
OmniAb, Inc. (OABIW) Fundamental Analysis - Meyka
Gainers Report: Why OmniAb Inc Equity Warrant stock could rally in 2025Forecast Cut & High Conviction Buy Zone Alerts - moha.gov.vn
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and OmniAb (OABI) - The Globe and Mail
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies - BioSpace
OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology PlatformSlideshow - Seeking Alpha
Transcript : OmniAb, Inc.Special Call - marketscreener.com
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment - simplywall.st
OmniAb unveils OmniUltra chickens at antibody conference - Traders Union
OmniAb (OABI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
There is no way OmniAb Inc (OABI) can keep these numbers up - setenews.com
Here's Why We're Not Too Worried About OmniAb's (NASDAQ:OABI) Cash Burn Situation - Yahoo Finance
OmniAb (OABI) chief legal officer Berkman sells $15,766 in stock By Investing.com - Investing.com Australia
OmniAb CFO Gustafson sells $46,887 in shares By Investing.com - Investing.com South Africa
Foehr, OmniAb CEO, sells $27k in shares By Investing.com - Investing.com South Africa
Foehr, OmniAb CEO, sells $27k in shares - Investing.com India
OmniAb (OABI) chief legal officer Berkman sells $15,766 in stock - Investing.com
OmniAb CFO Gustafson sells $46,887 in shares - Investing.com
OmniAb (NASDAQ:OABI) CFO Sells $46,887.12 in Stock - MarketBeat
OmniAb (NASDAQ:OABI) CEO Sells $26,785.36 in Stock - MarketBeat
OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 8,044 Shares - MarketBeat
OmniAb Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
CEO Foehr Acquires 12,888 Of OmniAb Inc [OABI] - TradingView — Track All Markets
CEO Foehr Files To Sell 13,666 Of OmniAb Inc [OABI] - TradingView — Track All Markets
Officer Berkman Files To Sell 8,044 Of OmniAb Inc [OABI] - TradingView — Track All Markets
Bull Bear: Will OmniAb Inc Equity Warrant stock beat EPS estimatesQuarterly Performance Summary & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
Big Picture: Why OmniAb Inc Equity Warrant stock attracts high net worth investorsJuly 2025 Spike Watch & Long-Term Growth Plans - moha.gov.vn
Is OmniAb Inc. a good long term investmentOptions Trading Strategies & These Stocks Are Just Getting Started - earlytimes.in
What analysts say about OmniAb Inc stockMarket Sentiment Surveys & Free Daily Stock Hotspot Analysis - earlytimes.in
Can OmniAb Inc. Equity Warrant stock continue upward trendPortfolio Value Summary & AI Enhanced Market Trend Forecasts - Newser
Comparing Wellgistics Health (NASDAQ:WGRX) and OmniAb (NASDAQ:OABI) - Defense World
Will OmniAb Inc. stock outperform value stocks2025 Market Outlook & Reliable Breakout Forecasts - Newser
OmniAb to Hold OmniUltra Virtual Investor Event on December 15 - Business Wire
Is OmniAb Inc. stock overvalued by current metricsFed Meeting & Real-Time Sentiment Analysis - Newser
Why OmniAb Inc. Equity Warrant stock attracts high net worth investorsBear Alert & Momentum Based Trading Ideas - Newser
Is OmniAb Inc. stock cheap compared to fundamentalsInsider Buying & Weekly Watchlist for Consistent Profits - Newser
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Berkman Charles S | Chief Legal Officer |
Dec 08 '25 |
Sale |
1.96 |
8,044 |
15,766 |
377,071 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Dec 07 '25 |
Option Exercise |
0.00 |
46,500 |
0 |
276,610 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Dec 08 '25 |
Sale |
1.96 |
23,922 |
46,887 |
252,688 |
| FOEHR MATTHEW W | President and CEO |
Dec 07 '25 |
Option Exercise |
0.00 |
26,554 |
0 |
4,373,749 |
| FOEHR MATTHEW W | President and CEO |
Dec 08 '25 |
Sale |
1.96 |
13,666 |
26,785 |
4,360,083 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):